Home > Resources > Trademark FAQs > Pharmaceutical Trademark Registration
Pharmaceutical Trademark Registration FAQs
This page explains pharmaceutical trademark selection and registration in India, including medicinal-mark confusion risk, INN and molecule-derived names, regulatory naming boundaries, examination and opposition, ownership and use evidence, packaging, well-known status, enforcement and international protection.
Important scope note. Pharmaceutical trademark clearance is not a substitute for drug-regulatory approval or product-safety review. Registrability, regulatory naming, actual use, packaging and patient-safety risks should be assessed separately and together before launch. This page provides general legal information, not regulatory, medical or legal advice for a particular product or name.
A. Pharmaceutical Naming Risk and Trademark Clearance
Confusion between medicinal products can have consequences beyond ordinary brand confusion. In Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., the Supreme Court stressed careful scrutiny of medicinal marks because confusion can affect patient safety. The comparison remains fact-specific and includes the marks as a whole, phonetic and visual resemblance, the nature and purpose of the products, likely purchasers, prescribing and dispensing conditions, and other surrounding circumstances.
No. Prescription status is relevant, but it does not eliminate confusion. Doctors, pharmacists, patients and others in the supply chain can still mishear, misread, misremember or incorrectly dispense similar medicinal names, so the practical prescribing and dispensing context remains part of the deceptive-similarity assessment.
Under the Nice Classification currently in force in 2026, Class 5 commonly covers pharmaceuticals and other preparations for medical or veterinary purposes, while Class 10 covers many medical apparatus and devices. Class 35 may be relevant for retail or wholesale services and related business services. Other classes may also matter, so classification should follow the actual goods and services rather than treating Class 5 as a universal pharmaceutical-business class.
A distinctive coined or arbitrary word that does not directly describe the active ingredient, therapeutic effect, indication, quality or other characteristics of the product is generally better positioned for registration and enforcement. Distinctiveness does not eliminate conflict risk, so even a coined mark should be cleared against earlier rights and the intended pharmaceutical naming context before adoption.
A clearance exercise should ordinarily cover exact, phonetic and structurally similar marks in the relevant classes; important prefixes, suffixes and recurring medicinal elements; pending and registered applications; relevant historical Registry records; notified International Nonproprietary Names; and material marketplace use. For a medicinal product, the legal search should be supplemented by a practical look-alike and sound-alike review in the intended prescribing, dispensing and packaging context.
Pharmaceutical names are often spoken, dictated, heard over telephone or recalled from memory rather than compared side by side. A spelling difference may therefore be insufficient where two names sound materially alike. Phonetic review should test likely Indian pronunciations, syllable structure, prefixes and suffixes, and the overall impression of the competing marks.
No. Their legal significance differs from that of a live application or registration, but they can still reveal earlier adoption, marketplace use, a recurring naming pattern or a possible prior-user claim. Clearance should distinguish Registry status from actual market rights instead of treating every historical record as either a complete bar or completely irrelevant.
B. INNs, Molecule-Derived Names and Regulatory Boundaries
Section 13 of the Trade Marks Act, 1999 prohibits registration of the commonly used and accepted name of a single chemical element or single chemical compound for a chemical substance or preparation. It also bars a word declared by the World Health Organization and notified by the Registrar as an International Nonproprietary Name, or a word deceptively similar to such an INN. The current notified INN material should therefore be checked before filing or launch.
It should not be assumed so. Section 13 extends to a word deceptively similar to a notified INN, and recent pharmaceutical trademark decisions have treated some clipped forms as non-exclusive or weak. But the outcome is mark-specific: not every fragment or combination derived from pharmaceutical terminology is automatically barred. The exact notified INN, the portion adopted, the mark as a whole, its registration history and the surrounding facts must be analysed.
Not necessarily. Registration does not turn a descriptive, generic, INN-derived or otherwise weak element into an unlimited monopoly. A molecule-derived mark may remain exposed to invalidity arguments, a narrower enforcement scope, descriptive or common-to-trade arguments, and conflict with earlier rights. Where a brand can be selected afresh, greater inherent distinctiveness usually reduces these risks.
No. Trademark registration and the permissions, licences and labelling requirements governing manufacture, import, marketing or sale of a drug arise under different legal regimes. A registered trademark does not by itself authorise manufacture or marketing of the product, and regulatory permission for a product does not by itself confer trademark priority or immunity from an earlier trademark claim.
This requires particular caution. Reusing an established pharmaceutical brand for a materially different composition can create trademark, labelling, product-identification and patient-safety concerns. As of 12 September 2026, CDSCO has also placed the issue of pharmaceutical brand-name extensions into stakeholder consultation through a public notice dated 6 July 2026. That consultation should not be treated as a final new prohibition; the current regulatory position should be checked when a proposed extension is assessed.
Yes, but a family-mark strategy does not make every extension safe. Each proposed variant should remain sufficiently distinguishable in its actual therapeutic and dispensing context, should not create a misleading impression about composition or use, and should undergo appropriate trademark and regulatory review. The naming architecture should reduce, rather than increase, the risk of product-selection or medication error.
C. Application, Examination and Opposition
Yes. Section 18 of the Trade Marks Act permits an application by a person claiming to be proprietor of a mark that is used or proposed to be used. Early filing can be commercially useful before packaging and launch expenditure, but ownership, specification of goods or services, intended use and the regulatory launch plan should remain aligned.
The application should be filed in the name of the person or entity legally entitled to claim proprietorship of the mark, not automatically in the name of the contract manufacturer. Brand ownership, manufacturing arrangements, licences or permitted-use arrangements, quality control and marketing or distribution rights should be documented consistently so that the Registry record matches the commercial ownership position.
Section 9 addresses absolute grounds such as lack of distinctive character, descriptive character, customary expressions and other statutory prohibitions. In a pharmaceutical context, a mark that merely describes an ingredient, therapeutic purpose, quality or characteristic may face an objection even where no earlier conflicting registration is cited. Acquired distinctiveness may be relevant in an appropriate case, but it should not be assumed to cure every absolute-ground problem.
Section 11 principally addresses conflict with earlier marks and likelihood of confusion. In a pharmaceutical case, the comparison should not be reduced to spelling differences: phonetics, the marks as a whole, nature and purpose of the goods, prescribing and dispensing conditions, purchasers, trade channels and the potential consequences of confusion can all matter.
Section 13 is a specific statutory prohibition concerning specified chemical names and notified International Nonproprietary Names, including words deceptively similar to notified INNs. Section 9 deals with absolute registrability grounds such as descriptiveness or lack of distinctiveness, while Section 11 addresses conflict with earlier trademark rights and likelihood of confusion. A pharmaceutical name can raise more than one of these provisions at the same time.
Under Rule 42 of the Trade Marks Rules, 2017, a notice of opposition in Form TM-O must be filed within four months from publication or re-publication of the application in the Trade Marks Journal. After the Registry serves a copy of the opposition, Rule 44 requires the applicant’s counter-statement in Form TM-O within two months from receipt. These are statutory deadlines and should be diarised independently of any settlement discussion.
The applicant should analyse the opponent’s earlier rights and use, the competing marks as a whole, common or weak elements, any INN or molecule-derived components, the goods and therapeutic context, trade channels, relevant consumers, evidence of honest adoption and use, and patient-safety implications. Depending on the facts, the strategy may include defending the application, narrowing the specification, negotiating a resolution, changing the mark or restructuring the portfolio.
No. Private consent can be relevant, and Section 12 allows registration in cases of honest concurrent use or other special circumstances subject to the Registrar’s discretion and conditions. But an agreement between traders does not displace the Registrar’s statutory duties or eliminate public-confusion and patient-safety concerns. The practical safety of coexistence should therefore be assessed separately from the parties’ willingness to agree.
D. Ownership, Use and Portfolio Protection
Indian trademark law preserves prior-user rights. Section 34 can protect continuous use that began before the registered proprietor’s relevant use or registration date, subject to its statutory conditions. Clearance and enforcement should therefore verify actual adoption and use evidence instead of assuming that the registration certificate alone resolves priority.
Useful records can include dated name-development and clearance material, internal approvals, trademark filings, regulatory records where relevant, manufacturing and marketing agreements, packaging approvals, labels and cartons, invoices, purchase orders, launch material, distributor records, advertisements, website captures, sales data and dated samples of actual use. Their evidentiary value depends on authenticity, continuity and the legal issue for which they are relied upon.
Yes. Section 47 provides specified non-use grounds for removal, including a continuous period of five years from the date the mark is actually entered in the register, measured up to three months before the non-use application, subject to the statutory provisions and exceptions. Special circumstances in the trade, including legal or regulatory restrictions, may be relevant, so regulatory delay or other constraints should be documented rather than assumed automatically to excuse non-use.
Not necessarily. The word mark is often the central asset, but a portfolio may also justify protection for a logo or device mark, composite label, distinctive packaging elements and relevant service marks. Each filing should correspond to a genuine brand asset and intended use, and a logo or label registration should not be treated as a substitute for clearing and, where appropriate, separately protecting the core word mark.
Potentially. Distinctive packaging, get-up, colour arrangements or overall presentation may acquire source-identifying significance and support trademark or passing-off claims, while common, descriptive or functional features are weaker. Word marks, device marks, artistic packaging and trade dress can involve different rights and evidentiary requirements and should be cleared and documented separately.
E. Well-Known Marks, Counterfeits and Enforcement
Yes, if the statutory evidence supports that status. Sections 11(6) to 11(9) identify relevant factors such as recognition among the relevant public, duration and geographical extent of use and promotion, registrations and successful enforcement. Rule 124 also permits a request to the Registrar in Form TM-M with supporting evidence for determination of a mark as well-known.
That shorthand is too broad. Section 11(2) can protect an earlier well-known mark against registration of an identical or similar mark for dissimilar goods or services where the statutory conditions are satisfied, including unfair advantage or detriment to the distinctive character or repute of the earlier mark. The actual scope therefore depends on the statutory test and the facts, not merely on attaching a ‘well-known’ label.
No. Registration creates important statutory rights, but enforcement depends on the validity and scope of the registration, competing marks and goods, priority and use, available defences, evidence and the remedy sought. Patient-safety considerations can materially affect the confusion and urgency analysis in medicinal-mark disputes, but interim or final relief still requires satisfaction of the applicable legal tests.
Trademark law and drug-regulatory law address different wrongs and may operate together. Trademark proceedings can address unauthorised use of identical or deceptively similar marks, false trademarks and passing off, while drug law and regulatory authorities address separate statutory categories such as spurious or misbranded drugs and licensing or safety violations. The facts should be mapped to each regime rather than using ‘counterfeit’ and ‘spurious’ as interchangeable labels.
F. International Protection and Practical Risk Control
No. Trademark rights are territorial. An Indian applicant planning overseas use should assess protection in each target market and may consider the Madrid Protocol where the eligibility and designation requirements are met. A Madrid filing does not create automatic substantive protection in every designated country, and drug-regulatory naming and marketing requirements in each market remain separate.
Common errors include adopting a name too close to an INN or molecule name; relying only on an exact-word search; ignoring phonetic and patient-safety risk; assuming Class 5 registration is drug approval; extending an established brand to a different formulation without fresh review; filing in the wrong commercial owner’s name; investing heavily in packaging before clearance; overlooking prior users; failing to preserve use evidence; and missing Journal or opposition deadlines. A coordinated trademark, regulatory and product-naming review before launch is usually more efficient than correcting the problem after market entry.
Related Information
If you have a proposed or existing pharmaceutical brand and need matter-specific review of trademark clearance, INN or molecule-name risk, filing strategy, opposition or enforcement options, you may send a preliminary enquiry.
Subject to conflict check, scope confirmation, professional terms and express acceptance by the responsible Advocate.
Last reviewed: 13 September 2026